Dr Reebye is involved in the development of therapeutic gain of function studies using novel RNA activation strategies. His work involves close collaboration with private biotechnology and international academic institutions both in the US and Asia. These versatile and powerful new tools for gene activation has shown an impact in experimental regenerative medicine by redirecting adult stem cells towards a surrogate insulin secreting phenotype and also in oncology by improving liver function and loss of tumour burden in cirrhotic models.
et al., 2021, Cannabinoids in the landscape of cancer, Journal of Cancer Research and Clinical Oncology, Vol:147, ISSN:0171-5216, Pages:2507-2534
et al., 2021, Up-regulation of C/EBP alpha inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients., Cancer Research, Vol:81, ISSN:0008-5472
et al., 2020, MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial, Clinical Cancer Research, Vol:26, ISSN:1078-0432, Pages:3936-3946
et al., 2020, Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), LIPPINCOTT WILLIAMS & WILKINS, ISSN:0732-183X
et al., 2020, Therapeutic saRNAstargeting CEBPA in Myeloid Cells. A potential Immunomodulatoryswitch for Anticancer Therapy, 23rd Annual Meeting of the American-Society-for-Gene-and-Cell-Therapy, CELL PRESS, Pages:51-52, ISSN:1525-0016